"All Things Peptides — Dr. Andrew Huberman" — Tim Ferriss

Why this is in the vault

Founder is actively on a GLP-1 protocol (tirzepatide since 2026-06-11) with a live gout/hydration interaction being tracked, and the vault already carries a peptides-101 note (Marchione) and a Lilly/retatrutide investing thesis. This clip is Huberman giving a tighter, more clinically skeptical second opinion on the same landscape — useful as a cross-check against Marchione's more bullish framing, and it independently corroborates the retatrutide/gray-market dynamics already investment-thesis-relevant to the LLY position.

Episode summary

Short promotional-style clip (11.5 min) from a longer Ferriss/Huberman interview, entirely focused on peptides: what they are, and Huberman's category-by-category read on GLP-1 agonists (incl. unreleased retatrutide), growth-hormone secretagogues (sermorelin, ipamorelin, CJC, MK-677), and BPC-157/TB-500 ("Wolverine stack"). Huberman is notably unbullish on secretagogues and BPC for general use, and repeatedly steers back toward "just get a script for real GH or testosterone" as the simpler, better-evidenced alternative.

Key arguments / segments

[00:00:00] Opening frame: peptides are short amino-acid chains (insulin is one); the "principle" borrowed from a prior guest (Abubakr, MD) is that pharma has shifted from mining plants for medicines to mining the body itself — GLP-1 agonists are the flagship example (circulating GLP raised ~1000x over baseline).
[00:02:00] Category 1 — GLP-1/weight-loss peptides: hundredfold GLP elevation treated diabetes without much weight loss; thousandfold+ elevation (Ozempic, Mounjaro) drives robust weight loss but also muscle loss and possible apathy/craving reduction. Lilly's unreleased retatrutide (hits GLP, GIP, and glucagon systems) is called the most effective of the class, with muscle-sparing claimed but unconfirmed.
[00:04:00] Gray-market retatrutide: already being sold/injected as "research use only" before formal approval because it's easy to synthesize; Huberman flags contamination risk (e.g., lipopolysaccharide) and "you may not be getting what you think you're getting."
[00:04:30] Category 2 — growth-hormone secretagogues (sermorelin, ipamorelin, tesamorelin, CJC, MK-677): typically a 3-8x GH/IGF-1 bump. Huberman self-reports trying sermorelin: big slow-wave sleep increase, wrecked REM, and an unexplained PSA spike that normalized after stopping — enough to make him not repeat the experiment.
[00:06:02] Huberman's verdict on secretagogues: not worth it personally; if someone can get a legitimate prescription, pharma-grade GH (somatropin/omnitrope) at 1-2 IU, 5 nights/week is the better-evidenced route for deep sleep, fat loss, tissue repair, and subjective well-being — versus stacking unverified secretagogue peptides.
[00:07:00] Category 3 — BPC-157 ("body protection compound"): amino acid chain from gastric juice; strong animal data (cartilage regrowth, fibroblast migration, angiogenesis, nerve regrowth) but Huberman states explicitly there is not a single published human trial. He's used it after strains and feels faster recovery but can't run a self-controlled experiment since it acts systemically, not locally.
[00:08:30] Sourcing: compounding pharmacies (he names Tailor Made, Upstate, Revive as reputable — no financial relationship disclosed) now fill BPC-157 or the related pentadecapeptide with a doctor's script; gray-market "research use only" is the riskier alternative. Notes Peptide Sciences shut down preemptively amid regulatory pressure.
[00:09:30] TB-500 + BPC-157 stack ("Wolverine stack"): Huberman has never tried TB-500; Ferriss used it post-elbow-surgery and says flatly he has no idea if it helped — recurring theme that self-experimentation with peptides can't be controlled.
[00:11:00] Closing line, echoing the open: for reliable fast recovery from exercise, Huberman's actual recommendation is 1-2 IU of prescription GH nightly before sleep — not the peptide stack.

Notable claims

Retatrutide (Lilly, unreleased) hits GLP-1, GIP, and glucagon receptors simultaneously and is described as the most effective weight-loss peptide of the class, with possible muscle-sparing (unconfirmed) [00:02:00-00:03:00].
Huberman: sermorelin produced a PSA spike with no offered mechanism, reversible on discontinuation — a specific, personally-observed adverse signal not commonly reported [00:05:00].
Huberman: BPC-157 has zero published human trials despite extensive positive animal literature — a stronger-than-usual "animal data ≠ human evidence" caution from a guest generally receptive to unconventional interventions [00:08:02].
Recurring epistemic point: self-experimentation with systemic peptides can't be locally controlled (can't inject one limb and not the other and compare), which both speakers flag as a fundamental limit on anecdotal peptide reports [00:07:00, 00:09:02].

Guests

Andrew Huberman, Ph.D. — Neuroscientist, tenured professor of Neurobiology and Ophthalmology at Stanford School of Medicine, runs the Huberman Lab, host of the Huberman Lab Podcast, author of Protocols: An Operating Manual for the Human Body.

Sponsorship

Standard Tim Ferriss Show pre-roll sponsor block (self/house-promo — not tied to peptide content, no conflict with the episode's subject matter): ProLon (fasting-mimicking diet), Eight Sleep (Pod Cover 5), Momentous (creatine), Helix Sleep (mattresses). No sponsor in this list sells peptides or competes with the content discussed.

Mapping against Ray Data Co

Direct feed into the founder's active health-and-longevity tracking: he's on tirzepatide (GLP-1 class) since 2026-06-11 with a monitored gout/hydration interaction, so Huberman's GLP-1 commentary (including the muscle-loss and craving-reduction side effects) is a useful clinical cross-check against the existing gout-management protocol. It also complements the Marchione peptides-101 note by adding a more skeptical, credentialed counterweight — Huberman explicitly downgrades growth-hormone secretagogues and steers toward simpler, better-evidenced interventions (prescription GH/testosterone) rather than the broader peptide stack Marchione is more bullish on. On the investing side, the retatrutide gray-market commentary (people already self-sourcing and injecting it pre-approval) is a minor corroborating data point for the LLY/GLP-1 longevity thesis's demand-signal argument, though not load-bearing enough to move that thesis on its own.

[[2026-05-11-marchione-peptides-101]] — more bullish peptide-category primer; this note is a useful skeptical counterweight from a credentialed academic source
[[2026-05-21-lilly-glp1-longevity-thesis]] — investing thesis this retatrutide/GLP-1 commentary corroborates
[[2026-06-24-gout-management-protocol]] — founder's active GLP-1-adjacent clinical protocol this content should be read against
[[2026-04-19-tim-ferriss-huberman-foundations-physical-mental-performance]] — prior Huberman/Ferriss vault entry, same show pairing

tim ferriss huberman peptides